AKT1 and acute myeloid leukemia: Consistent with these results, SNS-032 treatment elicited potent suppression of phosphorylation 4E-BP1 and p70S6K, the downstream targets of mTORC1, in AML cells and also reduced phosphor-Akt on Ser473, a substrate of mTORC2.